# Title

 Food and Drugs. PART 601â€”LICENSING


# ID

 CFR-2018-title21-vol7.Pt. 601


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                              |
|:------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'more than', 'maximum', 'less than', 'after', 'at least', 'greater', 'prior to']                                                                                                                                                                               |
| Duration    | ['15.0 day', '1.0 year', '60.0 day', '120.0 day', '30.0 day']                                                                                                                                                                                                                       |
| Condition   | ['until', 'unless', 'not subject to', 'where', 'subject to', 'when', 'if']                                                                                                                                                                                                          |
| Entities    | ['Approval', 'Pediatric', 'Such', 'Docket Number', 'Biological', 'Customs', 'Indications', 'Annual', 'Furnish', 'Random', 'Rockville, MD', 'Research, Office', 'Scope', 'Withdrawal', 'Issuance', 'Food', 'Failure', 'Electronic', 'Licenses', 'Rm', 'Research', 'Guidance', 'U.S'] |
| Date        | ['1999-12-20']                                                                                                                                                                                                                                                                      |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                   |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------------------|
| within        | The information must be submitted to FDA  within 30 working days of the biological product's withdrawal                                   |
| after         | If FDA determines,  after a biologics license application or supplement is filed,                                                         |
| after         | take either of the following actions: (1) Resubmission. after                                                                             |
| within        | either resubmit or withdraw the application or supplement within 1 year after issuance of a complete response                             |
| after         | withdraw the application or supplement within 1 year after issuance of a complete response letter to be                                   |
| within        | applicant's failure to resubmit the application or supplement within the extended time period or request an additional                    |
| within        | the applicant does not respond to the notification within 30 days, the application or supplement will be                                  |
| after         | following: (i) Authorized Food and Drug Administration employees after reasonable efforts have been unable to gain access                 |
| before        | achieve compliance with the requirements of this chapter, before proceedings will be instituted for the revocation of                     |
| before        | to the safety or effectiveness of the product. before                                                                                     |
| prior to      | of a supplement that does not require approval prior to distribution of the product or in an annual                                       |
| prior to      | (b) Changes requiring supplement submission and approval  prior to distribution of the product made using the change                      |
| prior to      | must obtain approval of the supplement from FDA prior to  distribution of the product made using the change.                              |
| at least      | (c) Changes requiring supplement submission  at least 30 days prior to distribution of the product                                        |
| prior to      | Changes requiring supplement submission at least 30 days prior to  distribution of the product made using the change.                     |
| less than     | product made using the change may begin not less than 30 days after receipt of the supplement by                                          |
| after         | change may begin not less than 30 days after  receipt of the supplement by FDA.                                                           |
| within        | (4) If  within 30 days following FDA's receipt of the supplement,                                                                         |
| prior to      | applicant that either: (i) The change requires approval prior to distribution of the product in accordance with paragraph                 |
| within        | applicant in an annual report submitted each year within 60 days of the anniversary date of approval                                      |
| prior to      | Blood Grouping Reagents requires supplement submission and approval prior to distribution of the product made using the change            |
| within        | (iv) A change  within the container closure system for a nonsterile product,                                                              |
| prior to      | submitted as a supplement requiring approval from FDA prior to distribution of the product which, if approved, may                        |
| before        | changes requiring supplement submission&#8212;FDA approval must be obtained before  distribution of the product with the labeling change. |
| prior to      | The applicant shall obtain approval from FDA  prior to  distribution of the product with the labeling change.                             |
| before        | with a labeling change that may be distributed before  FDA approval.                                                                      |
| prior to      | change normally requiring a supplement submission and approval prior to distribution of the product that FDA specifically requests        |
| greater       | analyses reveal risks of a different type or greater severity or frequency than previously included in submissions                        |
| prior to      | and obtain approval of the supplement by FDA prior to  distribution of the product made using the change.                                 |
| at least      | addresses in &#167;&#8201;600.2(c) of this chapter) must be at least  two final containers of each lot of product.                        |
| after         | issued or a biologics license application approved only after inspection of the establishment(s) listed in the biologics                  |
| after         | described in paragraph (a) of this section until after  licensing of the product for use in adults.                                       |
| before        | the product is ready for approval in adults before studies in pediatric patients are complete, pediatric studies                          |
| within        | requirement that the applicant submit the required assessments within  a specified time.                                                  |
| within        | products shall submit the following information each year within 60 days of the anniversary date of approval                              |
| more than     | biochemical, physiological, anatomical, or pathological process or to more than  one disease or condition.                                |
| within        | (5) For a claim that does not fall  within the indication categories identified in &#167;&#8201;601.33, the applicant                     |
| maximum       | The  maximum  tolerated dose need not be established.                                                                                     |
| after         | required postmarketing study with due diligence; (3) Use after marketing demonstrates that postmarketing restrictions are inadequate to   |
| within        | to file a written request for a hearing within 15 days of receipt of the notice, the                                                      |
| within        | who requests a hearing under this section must, within 30 days of receipt of the notice of                                                |
| before        | stay of action under &#167;&#8201;10.35 of this chapter. before                                                                           |
| within        | well as advertisements, intended for dissemination or publication within  120 days following marketing approval.                          |
| at least      | the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of                                |
| prior to      | must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the                             |
| after         | If FDA determines  after approval that the requirements established in &#167;&#8201;601.42, &#167;&#8201;601.43,                          |
| before        | be disclosed by the Food and Drug Administration before a biologics license application has been approved unless                          |
| before        | product file has been publicly disclosed or acknowledged before a license has been issued, no data or                                     |
| before        | product file has been publicly disclosed or acknowledged before a license has been issued, no data or                                     |
| after         | (1) All safety and effectiveness data and information. after                                                                              |
| within        | or study, unless it is shown to fall within the exemption established for trade secrets and confidential                                  |
| after         | consumer complaints, and other similar data and information, after deletion of: (i) Names and any information that                        |
| within        | compliance purpose and it is shown to fall within  the exemption established in &#167;&#8201;20.61 of this chapter.                       |
| after         | showing the manufacturer's testing of a particular lot, after deletion of data or information that would show                             |
| within        | from raw materials, costs, or other material falling within  &#167;&#8201;20.61 of this chapter.                                          |
| after         | application or a supplement to an application, or after  approval of an application or a supplement.                                      |
| within        | Postmarketing studies  within the meaning of this section are those that                                                                  |
| before        | The study was ended  before completion but a final study report has not                                                                   |
| within        | into by applicants shall be reported to FDA within 60 days of the anniversary date of the                                                 |
| within        | publicly disclose any information concerning a postmarketing study, within the meaning of this section, if the agency                     |
| after         | and field trials to study the product's efficacy after an accidental or hostile exposure have not been                                    |
| more than     | the product; (2) The effect is demonstrated in more than one animal species expected to react with a                                      |
| prior to      | with the product to be provided to patients prior to administration or dispensing of the biological product for                           |
| after         | the postmarketing study with due diligence; (3) Use after marketing demonstrates that postmarketing restrictions are inadequate to        |
| within        | to file a written request for a hearing within 15 days of receipt of the notice, the                                                      |
| within        | who requests a hearing under this section must, within 30 days of receipt of the notice of                                                |
| before        | stay of action under &#167;&#8201;10.35 of this chapter. before                                                                           |
| within        | well as advertisements, intended for dissemination or publication within  120 days following marketing approval.                          |
| at least      | the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of                                |
| prior to      | must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the                             |
| after         | If FDA determines  after approval under this subpart that the requirements established                                                    |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.0 year   | (1) FDA may consider a biologics license applicant or supplement applicant's failure to either resubmit or withdraw the application or supplement within 1 year after issuance of a complete response letter to be a request by the applicant to withdraw the application or supplement, unless the applicant has requested an extension of time in which to resubmit the application or supplement.                                                                 |
| 30.0 day   | The applicant will have 30 days from the date of the notification to explain why the application or supplement should not be withdrawn and to request an extension of time in which to resubmit the application or supplement.                                                                                                                                                                                                                                       |
| 30.0 day   | If the applicant does not respond to the notification within 30 days, the application or supplement will be deemed to be withdrawn.                                                                                                                                                                                                                                                                                                                                  |
| 30.0 day   | (c) Changes requiring supplement submission at least 30 days prior to distribution of the product made using the change.                                                                                                                                                                                                                                                                                                                                             |
| 30.0 day   | The supplement shall be labeled &#8220;Supplement&#8212;Changes Being Effected in 30 Days&#8221; or, if applicable under paragraph (c)(5) of this section, &#8220;Supplement&#8212;Changes Being Effected.&#8221;                                                                                                                                                                                                                                                    |
|            |               (2) These changes include, but are not limited to:                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               (i) [Reserved]                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (ii) An increase or decrease in production scale during finishing steps that involves different equipment; and                                                                                                                                                                                                                                                                                                                                         |
|            |               (iii) Replacement of equipment with that of similar, but not identical, design and operating principle that does not affect the process methodology or process operating parameters.                                                                                                                                                                                                                                                                   |
| 30.0 day   | (3) Pending approval of the supplement by FDA, and except as provided in paragraph (c)(5) of this section, distribution of the product made using the change may begin not less than 30 days after receipt of the supplement by FDA.                                                                                                                                                                                                                                 |
| 30.0 day   | (4) If within 30 days following FDA's receipt of the supplement, FDA informs the applicant that either:                                                                                                                                                                                                                                                                                                                                                              |
|            |               (i) The change requires approval prior to distribution of the product in accordance with paragraph (b) of this section; or                                                                                                                                                                                                                                                                                                                             |
|            |               (ii) Any of the information required under paragraph (c)(3) of this section is missing; the applicant shall not distribute the product made using the change until FDA determines that compliance with this section is achieved.                                                                                                                                                                                                                       |
| 60.0 day   | (1) Changes in the product, production process, quality controls, equipment, facilities, or responsible personnel that have a minimal potential to have an adverse effect on the identity, strength, quality, purity, or potency of the product as they may relate to the safety or effectiveness of the product shall be documented by the applicant in an annual report submitted each year within 60 days of the anniversary date of approval of the application. |
| 60.0 day   | Sponsors of licensed biological products shall submit the following information each year within 60 days of the anniversary date of approval of each product under the license to the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research (see mailing addresses in &#167;&#8201;600.2(a) or (b) of this chapter):                                                                                       |
|            |               (a) Summary.                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 15.0 day   | (1) If the applicant fails to file a written request for a hearing within 15 days of receipt of the notice, the applicant waives the opportunity for a hearing.                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | (3) An applicant who requests a hearing under this section must, within 30 days of receipt of the notice of opportunity for a hearing, submit the data and information upon which the applicant intends to rely at the hearing.                                                                                                                                                                                                                                      |
| 120.0 day  | For biological products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit to the agency for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval.                                                                |
| 120.0 day  | After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.                                                                                                                                                                                              |
| 30.0 day   | After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.                                                                                                                                                                                              |
| 60.0 day   | Annual progress reports for postmarketing study commitments entered into by applicants shall be reported to FDA within 60 days of the anniversary date of the U.S. approval of the application for the product.                                                                                                                                                                                                                                                      |
| 15.0 day   | (1) If the applicant fails to file a written request for a hearing within 15 days of receipt of the notice, the applicant waives the opportunity for a hearing.                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | (3) An applicant who requests a hearing under this section must, within 30 days of receipt of the notice of opportunity for a hearing, submit the data and information upon which the applicant intends to rely at the hearing.                                                                                                                                                                                                                                      |
| 120.0 day  | For biological products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit to the agency for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval.                                                                |
| 120.0 day  | After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.                                                                                                                                                                                              |
| 30.0 day   | After 120 days following marketing approval, unless otherwise informed by the agency, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement.                                                                                                                                                                                              |


## Condition

| Condition      | Context                                                                                                                                                            |
|:---------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| if             | forth in part 58 of this chapter, or, if the study was not conducted in compliance with                                                                            |
| not subject to | in part 56 of this chapter; or was not subject to such requirements in accordance with &#167;&#8201;56.104 or &#167;&#8201;56.105,                                 |
| if             | specimens of the labels, enclosures, and containers, and if applicable, any Medication Guide required under part 208                                               |
| until          | biologics license shall not be considered as filed until all pertinent information and data have been received                                                     |
| subject to     | of the following specified categories of biological products subject to licensure shall be handled as set forth in                                                 |
| subject to     | To obtain marketing approval for a biological product subject to licensure which is a therapeutic DNA plasmid product,                                             |
| subject to     | of establishments for the manufacture of a product subject to this section shall include but not be limited                                                        |
| if             | applicant or supplement applicant a complete response letter if the agency determines that it will not approve                                                     |
| unless         | the applicant to withdraw the application or supplement, unless the applicant has requested an extension of time                                                   |
| if             | to withdraw the application, the agency will not if y the applicant in writing.                                                                                    |
| until          | A biologics license shall be valid  until  suspended or revoked.                                                                                                   |
| if             | an opportunity for a hearing on, the decision. if                                                                                                                  |
| if             | (b)(1) The Commissioner shall not if y the licensed manufacturer of the intention to                                                                               |
| if             | in abeyance pending resolution of the matters involved. if                                                                                                         |
| subject to     | of this chapter has been revoked, shall be subject to the provisions of &#167;&#8201;314.200 of this chapter except                                                |
| when           | the hearing shall proceed on an expedited basis. when                                                                                                              |
| if             | of a supplement for public health reasons or if a delay in making the change described in                                                                          |
| if             | labeled &#8220;Supplement&#8212;Changes Being Effected in 30 Days&#8221; or, if applicable under paragraph (c)(5) of this section, &#8220;Supplement&#8212;Changes |
| if             | determines that compliance with this section is achieved. if                                                                                                       |
| until          | not distribute the product made using the change until FDA determines that compliance with this section is                                                         |
| if             | of the products made with the manufacturing change. if                                                                                                             |
| if             | FDA prior to distribution of the product which, if  approved, may just                                                                                             |
| if             | the package insert, package label, container label, or, if applicable, a Medication Guide required under part 208                                                  |
| if             | this section, information will be considered newly acquired if it consists of data, analyses, or other information                                                 |
| if             | this section, information will be considered newly acquired if it consists of data, analyses, or other information                                                 |
| if             | No product shall be licensed  if any part of the process of or relating                                                                                            |
| subject to     | biologics license application and each location shall be subject to  inspection by FDA officials.                                                                  |
| subject to     | Such persons and places shall be  subject to all regulations of this subchapter except &#167;&#167;&#8201;601.2 to                                                 |
| subject to     | shipment solely to a manufacturer of a product subject to licensure under &#167;&#8201;601.2(c), the following additional regulations shall                        |
| if             | not be needed in each pediatric age group, if data from one age group can be extrapolated                                                                          |
| until          | effectiveness described in paragraph (a) of this section until after licensing of the product for use in                                                           |
| if             | Deferral may be granted  if , among other reasons, the product is ready                                                                                            |
| until          | patients are complete, pediatric studies should be delayed until  additional safety or effectiveness data have been collected.                                     |
| if             | FDA determines that there is an adequate just if ication for temporarily delaying the submission of assessments                                                    |
| subject to     | product may be licensed for use in adults subject to the requirement that the applicant submit the required                                                        |
| if             | the requirements of paragraph (a) of this section if  the applicant cert                                                                                           |
| if             | of this section with respect to a spec if ied pediatric age group,                                                                                                 |
| if             | grant a full or partial waiver, as appropriate, if the agency finds that there is a reasonable                                                                     |
| if             | offer a meaningful therapeutic benefit over existing therapies if FDA estimates that: (i) If approved, the product                                                 |
| if             | offer a meaningful therapeutic benefit over existing therapies if FDA estimates that: (i) If approved, the product                                                 |
| if             | pediatric populations were required or agreed to, and, if so, the status of these studies shall be                                                                 |
| where          | In situations  where a particular radiopharmaceutical is proposed for both diagnostic                                                                              |
| where          | or to more than one disease or condition. where                                                                                                                    |
| when           | with the carrier or ligand of the radiopharmaceutical when the same chemical entity as the carrier or                                                              |
| subject to     | Approval under this section will be  subject to the requirement that the applicant study the biological                                                            |
| where          | further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of                                                             |
| if             | to be effective can be safely used only if distribution or use is restricted, FDA will require                                                                     |
| if             | to be effective can be safely used only if distribution or use is restricted, FDA will require                                                                     |
| if             | the applicant waives the opportunity for a hearing. if                                                                                                             |
| if             | accordance with &#167;&#167;&#8201;12.32(e) and 15.20 of this chapter. if                                                                                          |
| subject to     | Biological products approved under this program are  subject to the postmarketing recordkeeping and safety reporting applicable to                                 |
| unless         | products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit                                         |
| unless         | After 120 days following marketing approval,  unless otherwise informed by the agency, the applicant must                                                          |
| when           | under &#167;&#8201;601.41, these requirements will no longer apply when FDA determines that the required postmarketing study verifies                              |
| when           | under &#167;&#8201;601.42, the restrictions would no longer apply when FDA determines that safe use of the biological                                              |
| unless         | be disclosed by the Food and Drug Administration unless  it has previously been publicly disclosed or acknowledged.                                                |
| unless         | before a biologics license application has been approved unless  it has previously been publicly disclosed or acknowledged.                                        |
| if             | biological product file is available for public disclosure. if                                                                                                     |
| if             | are appropriate for public consideration of a spec if ic pending issue, e.g., at an open session                                                                   |
| unless         | product file are immediately available for public disclosure unless extraordinary circumstances are shown: (1) All safety and                                      |
| unless         | (2) A protocol for a test or study,  unless it is shown to fall within the exemption                                                                               |
| unless         | (5) An assay method or other analytical method,  unless it serves no regulatory or compliance purpose and                                                          |
| unless         | product file are not available for public disclosure unless they have been previously disclosed to the public                                                      |
| until          | of these postmarketing studies shall be reported annually until FDA notifies the applicant, in writing, that the                                                   |
| if             | approved product's proper name and the proprietary name, if  any.                                                                                                  |
| if             | as well as the reason(s) for the revision, if the schedule under paragraph (b)(7) of this section                                                                  |
| when           | (c) When to report. when                                                                                                                                           |
| where          | (d) Where to report. where                                                                                                                                         |
| if             | postmarketing study, within the meaning of this section, if the agency determines that the information is necessary                                                |
| if             | postmarketing study, within the meaning of this section, if the agency determines that the information is necessary                                                |
| when           | met based on adequate and well-controlled animal studies when the results of those animal studies establish that                                                   |
| unless         | to react with a response predictive for humans, unless the effect is demonstrated in a single animal                                                               |
| subject to     | (b) Approval under this subpart will be  subject to  three requirements:                                                                                           |
|                |               (1) Postmarketing studies.                                                                                                                           |
| when           | product's clinical benefit and to assess its safety when  used as indicated                                                                                        |
| when           | product's clinical benefit and to assess its safety when  used as indicated                                                                                        |
| until          | Such postmarketing studies would not be feasible  until  an exigency arises.                                                                                       |
| if             | under this subpart can be safely used only if distribution or use is restricted, FDA will require                                                                  |
| if             | product for the use approved under this subpart, if  possible.                                                                                                     |
| if             | the applicant waives the opportunity for a hearing. if                                                                                                             |
| if             | accordance with &#167;&#167;&#8201;12.32(e) and 15.20 of this chapter. if                                                                                          |
| subject to     | Biological products approved under this subpart are  subject to the postmarketing recordkeeping and safety reporting applicable to                                 |
| unless         | products being considered for approval under this subpart, unless otherwise informed by the agency, applicants must submit                                         |
| unless         | After 120 days following marketing approval,  unless otherwise informed by the agency, the applicant must                                                          |
| when           | under &#167;&#8201;601.91, these requirements will no longer apply when FDA determines that the postmarketing study verifies and                                   |
| when           | under &#167;&#8201;601.91, the restrictions would no longer apply when FDA determines that safe use of the biological                                              |


## Entities

| Entities         | Context                                                                                                                                       |
|:-----------------|:----------------------------------------------------------------------------------------------------------------------------------------------|
| Food             | Food  and Drugs.                                                                                                                              |
| Research         | to the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                                |
| Issuance         | Issuance  and denial of license.                                                                                                              |
| Furnish          | have been delivered of such suspension, and (2) Furnish to the Center for Biologics Evaluation and Research                                   |
| Research         | Furnish to the Center for Biologics Evaluation and Research  or the Center for Drug Evaluation and                                            |
| Licenses         | Licenses ; reissuance.                                                                                                                        |
| Research         | The Director, Center for Biologics Evaluation and  Research  or the Director, Center for Drug Evaluation and                                  |
| Electronic       | Electronic format submissions must be in a form that                                                                                          |
| Random           | Random samples of each importation, obtained by the District                                                                                  |
| Customs          | each importation, obtained by the District Director of Customs and forwarded to the Director, Center for Biologics                            |
| Research         | to the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                                |
| Research         | to the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                                |
| Research         | of the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                                |
| Food             | and places are registered with the Commissioner of Food and Drugs and it is found upon application                                            |
| Failure          | Failure of such manufacturer to maintain such procedures, inspections,                                                                        |
| Pediatric        | Pediatric  studies.                                                                                                                           |
| Annual           | Annual  reports of postmarketing pediatric studies.                                                                                           |
| Research         | to the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                                |
| Guidance         | Guidance  documents.                                                                                                                          |
| Research         | (b) The Center for Biologics Evaluation and  Research (CBER) maintains a list of guidance documents that                                      |
| Research, Office | and Drug Administration, Center for Biologics Evaluation and Research, Office of Communication, Outreach and Development, 10903 New Hampshire |
| Rm               | 71,  Rm .                                                                                                                                     |
| Scope            | Scope .                                                                                                                                       |
| Indications      | Indications .                                                                                                                                 |
| Such             | Such information may include, but is not limited to,                                                                                          |
| Scope            | Scope .                                                                                                                                       |
| Approval         | Approval based on a surrogate endpoint or on an                                                                                               |
| Approval         | Approval under this section will be subject to the                                                                                            |
| Approval         | Approval  with restrictions to assure safe use.                                                                                               |
| Withdrawal       | Withdrawal  procedures.                                                                                                                       |
| Food             | provide advice and recommendations to the Commissioner of Food  and Drugs.                                                                    |
| Biological       | Biological products approved under this program are subject to                                                                                |
| Docket Number    | IND that was required to be filed in Docket Number 95S-0158 in the Division of Dockets Management (HFA-305),                                  |
| Rockville, MD    | 1061,  Rockville, MD 20852, for investigations involving an exception from informed                                                           |
| Annual           | Annual  progress reports of postmarketing studies.                                                                                            |
| U.S              | the annual reporting interval which ends on the U.S . anniversary date.                                                                       |
| U.S              | (4) Date of  U.S . approval of BLA.                                                                                                           |
| U.S              | the study's status on the anniversary date of U.S . approval of the application or other agreed                                               |
| Annual           | Annual progress reports for postmarketing study commitments entered into                                                                      |
| U.S              | 60 days of the anniversary date of the U.S . approval of the application for the product.                                                     |
| Research         | studies to the Center for Biologics Evaluation and Research  or Center for Drug Evaluation and                                                |
| Scope            | Scope .                                                                                                                                       |
| Approval         | Approval based on evidence of effectiveness from studies in                                                                                   |
| Such             | Such postmarketing studies would not be feasible until an                                                                                     |
| Withdrawal       | Withdrawal  procedures.                                                                                                                       |
| Food             | provide advice and recommendations to the Commissioner of Food  and Drugs.                                                                    |
| Food             | The Commissioner of  Food and Drugs' decision constitutes final agency action from                                                            |
| Biological       | Biological products approved under this subpart are subject to                                                                                |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1999-12-20 | (e) Any establishment and product license for a biological product issued under section 351 of the Public Health Service Act (42 U.S.C. 201 et seq.) that has not been revoked or suspended as of December 20, 1999, shall constitute an approved biologics license application in effect under the same terms and conditions set forth in such product license and such portions of the establishment license relating to such product. |


